Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK5 | Q00535 | 4/20 | 0.56 |
| ▸ | CDK5R1 | Q15078 | 4/20 | 0.56 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.54 |
| ▸ | ESR1 | P03372 | 2/20 | 0.52 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.52 |
| ▸ | HSD17B1 | P14061 | 2/20 | 0.52 |
| ▸ | HSD17B2 | P37059 | 2/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.52 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
| ▸ | NPC1 | O15118 | 3/20 | 0.50 |
| ▸ | RAB9A | P51151 | 3/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6741892 | 0.87 | CYP19A1 (0.64) | CDK5CDK5R1ESR1ESR2NPC1 | |
| SCHEMBL11698946 | 0.86 | NPC1 (0.67) | RIPK1HSD17B1HSD17B2CYP1A2CYP2D6 | |
| SCHEMBL4258578 | 0.83 | CDK5 (0.71) | CDK5CDK5R1RIPK1ESR1ESR2 | |
| SCHEMBL34460152 | 0.78 | CYP26B1 (0.71) | RIPK1ESR1ESR2CYP3A4CYP2C9 | |
| SCHEMBL28281356 | 0.77 | CYP19A1 (0.60) | CDK5CDK5R1NPC1RAB9AKDM4E | |
| SCHEMBL16719993 | 0.76 | RIPK1 (0.48) | CDK5CDK5R1RIPK1ESR1ESR2 | |
| SCHEMBL19889776 | 0.74 | CDK5 (0.51) | CDK5CDK5R1KDM4EMEN1ALDH1A1 | |
| SCHEMBL27291636 | 0.73 | CDK1 (0.53) | CDK5CDK5R1ESR1ESR2KDM4E | |
| SCHEMBL29513345 | 0.73 | NPC1 (0.69) | NPC1RAB9AKDM4EMEN1ALDH1A1 | |
| SCHEMBL3708235 | 0.73 | NPC1 (0.63) | CDK5CDK5R1ESR1ESR2CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8546392-B2 | 17Beta-hydroxysteroid dehydrogenase type 1 inhibitors for the treatment of hormone-related diseases | UNIVERSITAET DES SAARLANDES (DE) | 2013-10-01 | — | — | US | disclosed |
| US-8546392-B2 | 17Beta-hydroxysteroid dehydrogenase type 1 inhibitors for the treatment of hormone-related diseases | UNIVERSITAET DES SAARLANDES (DE) | 2013-10-01 | — | — | US | disclosed |
| US-8546392-B2 | 17Beta-hydroxysteroid dehydrogenase type 1 inhibitors for the treatment of hormone-related diseases | UNIVERSITAET DES SAARLANDES (DE) | 2013-10-01 | — | — | US | disclosed |
| US-20100204234-A1 | 17Beta-Hydroxysteroid Dehydrogenase Type 1 Inhibitors for the Treatment of Hormone-Related Diseases | UNIVERSITAET DES SAARLANDES (DE) | 2010-08-12 | — | — | US | disclosed |
| US-20100204234-A1 | 17Beta-Hydroxysteroid Dehydrogenase Type 1 Inhibitors for the Treatment of Hormone-Related Diseases | UNIVERSITAET DES SAARLANDES (DE) | 2010-08-12 | — | — | US | disclosed |
| US-20100204234-A1 | 17Beta-Hydroxysteroid Dehydrogenase Type 1 Inhibitors for the Treatment of Hormone-Related Diseases | UNIVERSITAET DES SAARLANDES (DE) | 2010-08-12 | — | — | US | disclosed |
| WO-2008116920-A2 | 17BETA-HYDROXYSTEROID-DEHYDROGENASE TYPE 1 INHIBITORS FOR THE TREATMENT OF HORMONE-DEPENDENT DISEASES | Universität des Saarlandes (DE) | 2008-10-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100204234-A1 | 17Beta-Hydroxysteroid Dehydrogenase Type 1 Inhibitors for the Treatment of Hormone-Related Diseases | HSD17B1, HSD17B11, HSD17B2 | CDK5 1911/4885CDK5R1 1108/4885RIPK1 4354/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.